CompletedNCT01338818
Long-Term Safety of Extended-Release Methylphenidate in Adults With ADHD
About this title
Read the official source — NCT01338818Medication studyAges 18–60Multiple countries
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 47 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 299
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Belgium, Colombia, ...
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01338818
- Official title
Show the full official title
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Beverly Hills, United States · Spring Valley, United States
42 more locations
- Bradenton, United States
- Orlando, United States
- West Plam Beach, United States
- Libertyville, United States
- Owensboro, United States
- Las Vegas, United States
- Fargo, United States
- Columbus, United States
- Philadelphia, United States
- Houston, United States
- Bellevue, United States
- Seattle, United States
- Bruges, Belgium
- Heusden-Zolder, Belgium
- Uccle, Belgium
- Kessel-Lo, Belgium
- Mechelen, Belgium
- Santa Fe de Antioquia, Colombia
- Antioquia, Colombia
- Århus C, Denmark
- Bamberg, Germany
- Berlin, Germany
- Hamburg, Germany
- Ludwigsburg, Germany
- Mainz, Germany
- München, Germany
- Naumburg, Germany
- Nuremberg, Germany
- Wolfsburg, Germany
- Dresden, Germany
- Freiburg im Breisgau, Germany
- Homburg, Germany
- Landau, Germany
- Leipzig, Germany
- Limburg, Germany
- Mannheim, Germany
- Siegen, Germany
- Ulm, Germany
- Westerstede/Oldenburg, Germany
- Würzburg, Germany
- Luleå, Sweden
- Malmö, Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Ritalin LA (methylphenidate hydrochloride extended release).
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
MG01CI Compared With Placebo for ADHD in Adults